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Diﬀerent classes of breast cancers were explored for their positivity for growth hormone-releasing hormone receptors
(GHRH-R) in this pilot study, as no systematic evaluation of such tumors has been performed to date. Seventy-two
small primary breast carcinomas were evaluated for GHRH-R expression by immunohistochemistry using a polyclonal
antibody and a cutoﬀ value of 10% staining. GHRH-R positivity was detected in 58% of all cases, 20/23 (87%) of
invasive lobular carcinomas (ILC) and 22/46 (48%) of invasive ductal carcinomas (IDC). GHRH-R positivity was more
frequent in grade 2 tumors (86%), as compared to grade 1 (18%) or grade 3 (47%) cancers. GHRH-R expression was
not associated with mitotic scores, the Ki-67 labeling indices or nodal status. IDCs with casting-type calciﬁcations on
the mammogram showed positivity for GHRH-R in 9/12 (75%) cases. Most importantly, apocrine epithelium, and all
10 apocrine carcinomas added later to the study were GHRH-R-positive. These preliminary results suggest a greater
than average GHRH-R expression in ILCs and IDCs associated with casting-type calciﬁcations on the mammogram.
Apocrine carcinomas seem uniformly positive for GHRH-R. Whether these ﬁndings could indicate a potential role of
GHRH-antagonists in targeted treatment of these types of breast cancer requires further studies.
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Growth hormone-releasing hormone (GHRH) has
been implicated in carcinogenesis as a growth factor
acting both indirectly through the neuroendocrine
axis involving the pituitary release of growth hor-
mone (GH) with subsequent expression of insulin-
like growth factor 1 (IGF-1) in the liver, and more
signiﬁcantly directly through autocrine and para-
crine mechanisms. Many cancers of extrapituitary
tissues, including breast carcinomas express GHRH
and its receptors (1–3). The presence of both the
full length pituitary GHRH receptor (pGHRH-R)
and its splice variants, predominantly the splice var-
iant 1 (SV1) have been documented in breast cancer
(2, 4–6). As evidence of an autocrine/paracrine reg-
ulatory mechanism, it has been shown that the
knocking down of the GHRH gene expression in
breast cancer cell lines with SiRNA results in
reduced cellular proliferation (7). Similar eﬀects are
produced in prostate cancer and non-small cell lung
cancer cell lines (3, 7). As additional support for
autocrine/paracrine regulation is the transfection of
the MCF7 cells (originally devoid of GHRH-R)
with the GHRH-R which results in increased cellu-
lar proliferation after the addition of exogenousReceived 27 August 2013. Accepted 4 November 2013
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GHRH. This increase in proliferation is even
greater when the transfection involves the SV1
receptor (8). The transfection of MCF-7 cells with
the SV1 receptor results in increased proliferation
even without the addition of exogenous GHRH,
suggesting a GHRH-independent activation of this
truncated receptor (8). Furthermore, GHRH-R
antagonists have been found to be eﬀective in the
reduction of invasive and metastatic potential of
human cancer cell lines in vitro by modifying cellu-
lar adhesion, migration, and survival (9). The
antagonistic analogs of GHRH have been reported
to consistently reduce or abolish the growth of sev-
eral breast cancer models (6, 10, 11), and therefore
such antagonists have been proposed as potential
targeted therapeutic agents for breast carcinoma.
The presence of the pGHRH-R and/or the SV1
receptor in cancer cells has been demonstrated by
diﬀerent techniques including RT-PCR (2, 4, 11,
12), Western blotting (6, 12), in situ hybridization
(13), immunohistochemistry (5, 8, 13, 14) and ra-
dioreceptor assays (15). GHRH-Rs have been dem-
onstrated in estrogen receptor dependent as well as
independent breast carcinoma cell lines (11), in
both ductal and lobular carcinomas (5, 13), in duc-
tal carcinomas of various histological grades (5),
but no systematic evaluation of breast cancer types
has been performed to date.
There are diﬀerent approaches for the classiﬁca-
tion of breast cancer from conventional histopatho-
logical/morphological appearance to molecular
subtyping. The radiomorphological features of
breast tumors also reﬂect their biological behavior
and should be considered during disease manage-
ment (16). The presence of casting-type microcalci-
ﬁcation on the mammogram is a warning sign of
aggressive tumor behavior, irrespective of the stage
of the tumor (17, 18).
In this study, we analyzed a series of breast carci-
nomas for the expression of GHRH-R and corre-
lated the presence of these receptors to histological
features and morphological or biological subtypes
of breast cancers.
MATERIALS AND METHODS
In this retrospective study, tissue blocks of 71 breast can-
cer patients from the archives of the Department of
Pathology, University of Szeged were used. These were
obtained either from total mastectomy or from partial
mastectomy specimens. Only carcinomas ≤2 cm (pT1
tumors) (19, 20), were included in the study to limit the
eﬀect of tumor heterogeneity. Groups of diﬀerent histolog-
ical, molecular and clinicopathological types of breast can-
cer were selected. Histological types included invasive
tubular, ductal (no special type, NST) and lobular (ILC)
carcinomas as deﬁned by the World Health Organization
(WHO) classiﬁcation of breast tumors (21). Grading was
performed on the basis of the Nottingham scheme (22).
Molecular types were determined by means of the surro-
gate immunohistochemistry (IHC)-based approach using
estrogen receptor (ER), progesterone receptor (PR),
human epidermal growth factor receptor 2 (HER2) and
Ki-67 to classify breast carcinomas into luminal A, lumi-
nal B, HER2-enriched and triple-negative (including the
basal-like) subtypes (23, 24). The antisera technologies of
companies shown in Table 1 were used. On this basis,
ER-positive tumors were classiﬁed as luminal A if they
were HER2-negative and had a Ki-67 labeling index
<14%; they were labeled as luminal B if they were either
HER2-positive or had a Ki-67 labeling index >13% or
both. ER-negative tumors were classiﬁed either as HER2-
positive or as triple-negative (HER2-negative and PR-neg-
ative). Cases with casting-type microcalciﬁcation on the
mammogram were also included in the study because
these tumors have been reported to have an unfavorable
outcome by some authors (16–18), and they are consid-
ered as a special entity by the multidisciplinary breast
team at the University of Szeged. During the selection of
the cases, we added to the study material 10 cases of carci-
nomas (of any size) with apocrine diﬀerentiation (apocrine
carcinomas) recently diagnosed at the Department of
Pathology, University of Szeged or at the Department of
Pathology, Bacs-Kiskun County Teaching Hospital.
Tissues were ﬁxed in buﬀered formalin and embedded
in paraﬃn. Four- to ﬁve-micrometer-thick whole tissue
sections were used for the immunohistochemistry. The
antibodies used are listed in Table 1. The stains for ER,
PR, HER2 and in most cases Ki-67 were performed rou-
tinely and the results were available from the original
reports. The interpretation of the ER, PR and HER2 sta-
inings was according to the American Society of Clinical
Oncology/College of American Pathologists guidelines (25,
26). Details of the anti-GHRH-R immunohistochemistry
were as follows.
Deparaﬃnization (in xylene for 3 9 3 min, in 96% eth-
anol for 2 9 3 min and in 70% ethanol for 3 min) fol-
lowed by rehydration (2 9 2 min distilled water) at room
temperature was followed by antigen retrieval with the
Dako PT Link system (Dako, Glostrup, Denmark)
(10 mM Sodium Citrate buﬀer, pH 6 for 15 min at
94 °C). After being rinsed with Tris buﬀer saline – EnVi-
sion FLEX Wash (TBS) (Dako), the sections were placed
in Dako Autostainer Link 48 (Dako) for endogenous
Table 1. List and details of antibodies used





















Ki-67 MIB-1 DAKO 1:100
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peroxidase blockage and staining. In the Autostainer, the
sections were washed with TBS, blocked by FLEX Peroxi-
dase-Blocking Reagent (Dako) (for 5 min), incubated with
the rabbit anti-GHRH-R polyclonal antibody at 56°C
(diluted at 1:250) for 50 min, rinsed (in TBS for 10 min),
and then incubated with the Dako EnVision FLEX (Rab-
bit) detection system (Dako) (in secondary antibody for
30 min, TBS, in DAB+ for 2 9 7 min, TBS). The sections
were then counterstained with Mayer’s hematoxylin, dehy-
drated (in 96% ethanol for 3 9 3 min, in acetone for
2 9 3 min), cleared in xylene (for 2 9 2 min), and
mounted. Negative controls were carried out by omitting
the primary antibody. Every slide included a pituitary
gland tissue-chip to serve as positive control.
Specimens were evaluated only in the case of adequate
staining in the controls. Positive staining of breast cancer
tissue was classiﬁed according to the localization of
immune reaction and percentage of positive tumor cells.
On the basis of a previous report, both nuclear and cyto-
plasmic stainings were accepted as positive (13). The inva-
sive component of the tumors was evaluated, and
specimens below the cutoﬀ level of 10% staining were
considered negative.
Statistical analysis was performed with the chi-square
test using the SPSS 20.0 (IBM, Armonk, NY, USA) statis-
tical software, and the signiﬁcance level chosen was
p < 0.05.
Since all patient and disease information was gathered
anonymously and retrospectively with no inﬂuence on
patient outcome or treatment, no ethical permission was
deemed necessary according to local regulations.
RESULTS
Seventy-one early breast cancer patients (one bilat-
eral case) with 72 tumors were included in the pres-
ent study. The clinicopathological features are
summarized in Table 2.
Cytoplasmic, nuclear, or combined GHRH posi-
tivity was detected in 42/72 (0.58) of the cases.
Considering the most common histological types
(tubular carcinomas were lumped together with
NST ductal carcinomas), ILCs displayed GHRH-R
positivity more often than ductal carcinomas: 20/23
(0.87; 95% conﬁdence interval (CI): 0.68–0.95) vs
22/46 (0.48; 95% CI: 0.34–0.62) (p = 0.002, Pearson
chi-square). Five of the ILCs were pleomorphic on
the basis of cellular morphology and combined his-
tological grade 3; all were positive for GHRH-R.
Positivity of staining according to the histological
grade of the tumors is shown in Fig. 1. Interest-
ingly, the highest proportion of tumors demonstrat-
ing GHRH-R positivity (25/29; 0.86; 95% CI:
0.69–0.95) was seen in grade 2 carcinomas, whereas
this proportion was lower for grade 1 (2/11; 0.18;
95% CI: 0.05–0.48) and grade 3 (15/32; 0.47; 95%
CI: 0.31–0.64) tumors. To assess the relation of
GHRH-R expression and proliferation, the mitotic
score was used, as an ordinal variable standardizing
mitotic counts to the area of the high power ﬁeld
of the microscopes, but no association was found
Table 2. Basic characteristics of the patients and tumors
Age: median (range) 61 years (32–88)









Others (medullary, sarcomatoid) 3 (2, 1)
Histological grade
Grade 1 11 (15.3%)
Grade 2 29 (40.2%)
Grade 3 32 (44.4%)
IHC-based molecular types





Triple negative (inclusive of
basal-like)
19 (26.4%)











Fig. 1. Distribution of GHRH-R-positive and GHRH-R-
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Fig. 2. Distribution of GHRH-R-positive and GHRH-R-
negative cases according to the mitotic score component
of the histological grade of breast carcinomas.
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(Fig. 2). Similarly, there was no signiﬁcant diﬀer-
ence in the Ki-67 labeling indices (LI) of GHRH-R
positive and negative tumors, where the average
LIs were 18.3 and 28.3, respectively (p = 0.18),
although Ki-67 LIs were available in only 51 cases.
There was no association between nodal status
and GRHR-R staining: 13/42 (0.31; 95% CI: 0.19–
0.46) of the GHRH-R-positive tumors were node-
positive, and this proportion was 12/30 (0.4; 95%
CI: 0.25–0.58) for the GHRH-R-negative cases
(p = 0.43, Pearson chi-square).
According to the IHC-based surrogate molecular
classiﬁcation, GHRH-R positivity was observed in
17/28 (0.61; 95% CI: 0.42–0.76) luminal A (ER-
positive, HER2-negative, Ki-67 < 14%), 8/9 (0.89;
95% CI: 0.57–0.98) luminal B (ER-positive and
either HER2-positive or Ki-67 > 13% or both), 7/
12 (0.58; 95% CI: 0.32–0.081) HER2-enriched (ER-
negative and HER2-positive) and 6/19 (0.32%;
95% CI: 0.15–0.54) triple-negative carcinomas (ER-
negative, PR-negative and HER2-negative) (Fig. 3).
The luminal B tumor with negative GHRH-R sta-
tus was a HER2-negative carcinoma with high pro-
liferation rate (Ki-67 labeling: 25%).
As a special clinical entity, 12 tumors with cast-
ing-type calciﬁcations on the mammogram were
also included in the study. Nine of these cases
showed GHRH-R positivity (0.75; 95% CI: 0.47–
0.91). The carcinomas with casting-type calciﬁca-
tions represented NST ductal carcinomas, with het-
erogeneity in terms of hormone receptor (seven
were ER-positive and ﬁve of these were also PR-
positive) and HER2 status (four were positive). As
concerns the molecular types according to the IHC-
based classiﬁcation, all four types were represented.
The GHRH-R-negative cases belonged to the lumi-
nal A (n = 2) or the HER2-enriched (n = 1) types.
During the analysis of the cases, we observed a
consistent and strong staining for GHRH-R in foci
of apocrine metaplasia (Fig. 4). To investigate this
unanticipated phenomenon, we included 10 cases of
recently diagnosed apocrine carcinomas – as
deﬁned by the recent WHO classiﬁcation of breast
tumors (21), all of which showed strong and diﬀuse
GHRH-R positivity (Fig. 4). All the apocrine carci-
nomas studied were negative for ER and PR; seven
of them were HER2-negative as well, whereas two
tumors were positive for HER2 and one case of
apocrine ductal carcinoma in situ apocrine was not
tested for this marker. All 10 cases were positive
for the apocrine marker GCDPF-15 and four cases
tested for androgen receptor were all positive. No
attempts were made in this study to distinguish
between pGHRH-R and SV1 since this would
require the use of more speciﬁc antisera for IHC
which are still under development.
DISCUSSION
The endocrine eﬀect of GHRH on cancer has been
thought to be rendered by the stimulation of the
GHRH/GH/IGF-1 axis. Recently, an additional
autocrine/paracrine role in the regulation of prolif-
eration and diﬀerentiation of cancer cells has been
proposed. The latter mechanism is supported by
the presence of GHRH in various malignancies as
demonstrated by means of mRNA expression by
the detection of immuno-reactive and biologically
active GHRH and by the identiﬁcation of its recep-
tors in diﬀerent human cancers (1–4, 12). GHRH
antagonists have been tested as potential targeted
therapeutic agents in several malignancies, including
breast cancers (6, 10, 11).
The incidence of GHRH-R expression in diﬀer-
ent breast cancer subtypes (histological, molecular
and clinical) has not yet been investigated exten-
sively. Since the presence of the GHRH-R could be
a selection criterion for potential treatment targeted
to GHRH-R, it was thought that a pilot study
identifying potential subsets of tumors preferen-
tially expressing the receptor could be of relevance.
To elucidate the possible presence of GHRH-R in
the individual subtypes, we selected tissue blocks of
diﬀerent histological and molecular types from our
archives, and examined the expression of GHRH-R
with IHC.
As concerns the diﬀerent histologic types of
breast cancer, there are many based on special fea-
tures, but the two major types are ductal carcino-
mas NST and lobular carcinomas. Other subtypes
are less frequent, and are sometimes viewed as spe-
cial types of ductal (non-lobular) carcinomas. In
our study, ILCs were signiﬁcantly more frequently
positive for GHRH-R. A previous report has iden-
tiﬁed lobular carcinomas to have a higher rate of
GHRH expression than ductal carcinomas, which











Luminal A Luminal B HER2-enriched Triple negative
GHRH-R +
GHRH-R –
Fig. 3. Distribution of GHRH-R-positive and GHRH-R-
negative cases according to the molecular subtypes of
breast carcinomas determined by IHC.
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eﬀect. The same study failed to document a similar
predilection for the distribution of SV1 using a
polyclonal antibody which is no longer available
(5). In that study, only 1 of 6 lobular carcinomas
was positive for SV1. The contrary ﬁnding that
most ILCs were positive for GHRH-R in our
analysis, could probably be explained by the use of
a diﬀerent antibody that detects both the pGHRH-
R and the SV1 receptor. Since the antibody
(ab76263) used in our study was raised against a
synthetic peptide derived from the internal region
of the human pGHRH-R (27), and the biologically
active SV1 diﬀers from the full length pituitary
receptor only in its N-terminal part (2), the anti-
body recognizes the full length GRHR-R along
with the SV1, but not the much shorter (145-amino
acid-long) SV2.
As concerns the grades of diﬀerentiation of
breast cancer, no signiﬁcant association was found
with the GHRH-R status, although grade 2 tumors
seemed to show GHRH-R positivity more fre-
quently than grade 1 or 3 tumors. Reports on the
distribution of GHRH-R by grade are scarce. Chat-
zistamou et al. suggested no predilection for any
level of diﬀerentiation: 2/2 of grade 1, 5/16 of grade
2, and 6/22 of grade 3 ductal carcinomas were iden-
tiﬁed as positive (5). The reasons for ﬁnding more
positive cases among grade 2 tumors are not clear,
especially in the light of molecular studies. Sotiriou
and colleagues have demonstrated that gene expres-
sion proﬁle-based genomic grades matched well
histological grades 1 and 3, but breast tumors clas-
siﬁed as histological grade 2 fell either into the cate-
gory of low or high genomic grade (28). Therefore,
histologic grade 2 tumors cannot be classiﬁed mor-
phologically into high or low grade, resulting in an
intermediate prognosis due to this dual composi-
tion. Our results, as well as the previous report
cited, suggest that GHRH-R positivity can occur in
any grade of breast cancer, and there seems to be
no real predilection for any grade. In keeping with
the results relating to the diﬀerentiation of the car-
cinomas, no association was found with prolifera-
tion whether assessed by mitotic scores or the
Ki-67 proliferation marker. There was also no asso-
ciation of GHRH-R expression and the nodal
status of breast carcinomas.
The study also incorporated 12 cases with cast-
ing-type microcalciﬁcation on the mammogram.
The clinical outcome of this entity is still subject to
some debate with some authors and results rein-
forcing the ﬁnding of a poor outcome (16–18, 29–
31) and others refuting it (32, 33). Our experience
supports the poor outcome of these tumors, and is
why such cases were separately studied for their
GHRH-R expression (18). Although the authors
originally describing this entity as one associated
with poor prognosis did not speciﬁcally report the
distribution of this type of carcinoma presentation
according to molecular subtypes, they suggested
that many of these tumors were HER2-positive
(17), with HER2 positivity being three times more
A B
C D
Fig. 4. Examples of GHRH-R positivity in diﬀerent histological entities. (A) lobular carcinoma (GHRH-R x20); (B) apo-
crine cyst (GHRH-R x10); (C–D) no special type (ductal) carcinoma with apocrine diﬀerentiation, i.e., apocrine carcinoma
(C: GHRH-R x20, D: HE x40).
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frequent in this subgroup than in breast carcinomas
without casting-type calciﬁcations (Tot T., personal
communication 2013 July). The present series of
small tumors included carcinomas with casting-type
microcalciﬁcations with heterogeneous grade and
molecular type distribution, and only one-third
were HER2-positive. All cases with casting-type
calciﬁcations were associated with high grade ductal
carcinoma in situ showing comedo necrosis and mi-
crocalciﬁcation. GHRH-R positivity was observed
in 75% of the cases of this clinical/mammographi-
cal entity which is almost double the 40% positivity
rate of ductal NST carcinomas without casting-type
microcalciﬁcation; this diﬀerence failed to be statis-
tically signiﬁcant. The relevance of these ﬁndings is
not yet known, but further study is warranted to
clarify this issue.
Growth hormone-releasing hormone receptors
positivity was seen in all molecular types of breast
cancer, including ER-positive and ER-negative
cases, in keeping with results found with cell lines
(11). All but one of the luminal B tumors demon-
strated strong and diﬀuse immune reaction with
anti-GHRH-R, but as even luminal B tumors are
heterogeneous, the signiﬁcance of this ﬁnding in a
relatively low number of cases is uncertain.
Even though triple-negative breast cancers
showed GHRH-R positivity in a relatively low per-
centage (32%), the unfavorable prognosis and the
limited therapeutic modalities for these carcinomas
emphasize the importance of this group. Targeted
anti-GHRH therapy proved to be eﬃcient in the
treatment of nude mice transplanted with human
triple-negative breast cancer xenografts (34). Fur-
ther investigations are necessary to clarify whether
triple-negative cancers expressing the GHRH-R
could be treated with GHRH antagonists.
As a caveat, it must be remembered that the
present pilot study did not include consecutively
diagnosed breast carcinomas, and therefore the pro-
portion of staining tumors may only be an esti-
mate, requiring conﬁrmation on a larger group of
tumors. A strength, however, is that we chose to
limit tumor heterogeneity by studying relatively
small (pT1) cancers.
During the analysis of the cases, we noticed a pro-
nounced, uniform GHRH-R expression in cysts
showing apocrine metaplasia. This ﬁnding inspired
us to investigate the expression of GHRH-R in can-
cers showing apocrine diﬀerentiation and to include
10 cases of apocrine carcinoma (both in situ and
invasive tumors). All of these consistently demon-
strated a strong and diﬀuse positivity. Apocrine car-
cinomas are deﬁned as carcinomas in which the cells
demonstrate the cytological features of apocrine cells
(21), they are often ER-negative and PR-negative,
but androgen receptor (AR)-positive tumors (35),
and express apocrine markers like gross cystic dis-
ease ﬂuid protein-15 (GCDFP-15). As concerns the
molecular types approached by IHC, a part of these
neoplasms belongs to the HER2-enriched group, but
the majority of them are triple negative. A molecular
apocrine type of breast cancers with increased
androgen signaling has also been described, and is
characterized by ER negativity and AR positivity
(21, 36–38). The overlap between breast cancers clas-
siﬁed as apocrine on the basis of gene expression
proﬁle vs morphologic features is not complete. It
has been estimated that the apocrine gene expression
proﬁle may be present in 8–14% of breast cancers,
whereas apocrine carcinomas classiﬁed on the basis
of morphologic appearance are relatively rare, com-
prising about 4% of breast carcinomas (21); part of
them may be a subset of triple-negative breast can-
cers. Their androgen-dependent signaling pathway
could also suggest a speciﬁc treatment. Whether
their homogeneous positivity for GHRH-R can be
translated to a targeted therapy with GHRH antag-
onists which are under development for clinical use
requires further studies.
CONCLUSION
Our study demonstrates that the distribution of
GHRH-R among breast carcinomas is not
restricted to histological type, diﬀerentiation grades
or molecular subtypes. ILCs were found to express
this marker more frequently than ductal NST carci-
nomas. The ﬁnding of a relatively high proportion
of positivity among ductal NST carcinomas with
casting-type microcalciﬁcation is of uncertain signif-
icance. The most important ﬁnding of this study,
we feel is that apocrine epithelium (both benign
and malignant) stains diﬀusely and strongly for
GHRH-R. Whether this phenomenon can be used
for targeting apocrine carcinomas with GHRH
antagonists is to be clariﬁed in future studies.
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